Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

Market Segmentation: The report may break down the market into segments based on gene delivery methods (e.g., viral vectors, non-viral vectors), applications (e.g., gene therapy, research, vaccines), ...

Scientists at the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard have re-engineered ...

Researchers at the Max Planck Institute for Evolutionary Anthropology have addressed a longstanding challenge in CRISPR ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas ... Although Cas12f proteins benefit from compact size for delivery, their gene-editing activity remains limited. By adding an N-terminal α ...

ACVR2A downregulation disrupts the TCF7/c-JUN pathway, impairing trophoblast invasion and proliferation in pre-eclampsia, revealing a genetic susceptibility-associated mechanism of placental ...

The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...

There are a variety of mRNA delivery methods that have been developed in an attempt to navigate the challenges, such as direct injection of naked mRNA, lipid-based carriers, polymers, and protein ...